Danish study of Non-Invasive testing in Coronary Artery Disease 2 (Dan-NICAD 2) is expected to contribute to the improvement of diagnostic strategies for patients suspected of coronary artery disease. In this touchCARDIO interview, we speak with Dr Morten Bøttcher (Aarhus University, Aarhus, Denmark) to discuss the aims and findings of the Dan-NICAD 2 study and the implications for clinical practice.
The abstract entitled ‘DanNICAD-2 – Perfusion scanning with MR or PET after a positive CT coronary angiography’ was presented at the European Society of Cardiology (ESC) Congress 2022, 26 – 29 August 2022.
- What were the aims and design of the Dan-NICAD 2 study? (0:16)
- What were the study findings? (1:36)
- How will these findings impact clinical practice? (3:30)
Disclosures: Morten Bøttcher is on the advisory board for Acarix, AstraZeneca, Bayer, Novartis, Novo Nordisk and Sanofi.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of ESC 2022
Access more content on Cardiovascular Disease here
Share this Video
Related Videos In Cardiovascular Disease
Divaka Perera, ESC 2022: Percutaneous revascularisation in patients with severe ischaemic cardiomyopathy, the REVIVED trial
The REVIVED study aimed to assess whether the addition of stents when treating patients with severe ischaemic cardiomyopathy would be beneficial to patient outcomes. In this touchCARDIO interview, we speak with Professor Divaka Perera (King’s College London, London, UK) to discuss the REVIVED trial, its outcomes and how they will affect the current treatment paradigm. […]
Divaka Perera, ESC 2022: The unmet needs in patients with heart failure due to ischaemic cardiomyopathy
In an ideal scenario, patients with ischaemic cardiomyopathy would receive specific treatment options beyond the general heart failure management currently in place. In this touchCARDIO interview, we speak with Professor Divaka Perera (King’s College London, London, UK) to discuss the unmet needs in this population and give an evaluation of surgical and percutaneous revascularization in […]
Isla Mackenzie, ESC 2022: Allopurinol for ischaemic heart disease, the ALL-HEART study
The ALL-HEART study is the first large, randomised trial assessing allopurinol in patients with ischaemic heart disease. In this touchCARDIO interview, we speak with Professor Isla Mackenzie (University of Dundee, Dundee, Scotland) to discuss the rationale for the ALL-HEART study, its findings and the future of allopurinol in ischaemic heart disease. The abstract entitled ‘ALL-HEART […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!